MabGenesis Inc. (headquartered in Yokohama, Kanagawa; Representative Director: Katsuhiro Shinjo), an investee company of a fund managed by Beyond Next Ventures Inc., was listed on the Growth Market of the Tokyo Stock Exchange on November 2, 2026.

MabGenesis aims to be an innovator in the field of veterinary antibody therapeutics. Under its mission of helping alleviate symptoms and improve the quality of life of companion animals and people affected by disease through the provision of innovative antibody drugs based on the latest medical knowledge and proprietary core technologies, the company is engaged in the development of antibody drugs for animals.

MabGenesis news release: https://mabgenesis.com/en/news/20261102-notice-regarding-listing-on-tse-growth-market